Scholarlink

<p>Epitope-based vaccines are promising therapeutic modalities for infectious diseases and cancer, but identifying immunogenic epitopes is challenging. Most prediction methods only use amino acid sequence information, and do not incorporate wide-scale structure data and biochemical properties across each peptide–major histocompatibility complex (MHC). We present ImmunoStruct, a deep learning model that integrates sequence, structural and biochemical information to predict multi-allele class I peptide–MHC immunogenicity. By leveraging a multimodal dataset of 26,049 peptide–MHCs, we demonstrate that ImmunoStruct improves immunogenicity prediction performance and interpretability beyond existing methods, across infectious disease epitopes and cancer neoepitopes. We further show strong alignment with in vitro assay results for a set of SARS-CoV-2 epitopes, as well as strong performance in peptide–MHC-based survival prediction for patients with cancer. Overall, this work also presents an architecture that incorporates equivariant graph processing and multimodal data integration for a long-standing challenge in immunotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

ImmunoStruct enables multimodal deep learning for immunogenicity prediction

  • 期刊论文

  • 发表日期：

    2025年12月31日

查看全文
  • Kevin Bijan Givechian,
  • João Felipe Rocha,
  • Chen Liu,
  • Edward Yang,
  • Sidharth Tyagi,
  • Kerrie Greene,
  • Rex Ying,
  • Etienne Caron,
  • Akiko Iwasaki,
  • Smita Krishnaswamy

摘要

Epitope-based vaccines are promising therapeutic modalities for infectious diseases and cancer, but identifying immunogenic epitopes is challenging. Most prediction methods only use amino acid sequence information, and do not incorporate wide-scale structure data and biochemical properties across each peptide–major histocompatibility complex (MHC). We present ImmunoStruct, a deep learning model that integrates sequence, structural and biochemical information to predict multi-allele class I peptide–MHC immunogenicity. By leveraging a multimodal dataset of 26,049 peptide–MHCs, we demonstrate that ImmunoStruct improves immunogenicity prediction performance and interpretability beyond existing methods, across infectious disease epitopes and cancer neoepitopes. We further show strong alignment with in vitro assay results for a set of SARS-CoV-2 epitopes, as well as strong performance in peptide–MHC-based survival prediction for patients with cancer. Overall, this work also presents an architecture that incorporates equivariant graph processing and multimodal data integration for a long-standing challenge in immunotherapy.